AMAli Manouchehri

Ali Manouchehri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ali Manouchehri has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Joe-Elie Salem

    Research Institute of Cardiovascular Disease, Metabolism and Nutrition, Faculté de Médecine—Hôpital Pitié-Salpêtrière, Sorbonne University, Inserm, UMR_S1166 , 91 boulevard de l'Hôpital, 75013 Paris

    5 shared publications
  • Javid J. Moslehi

    Section of Cardio-Oncology & Immunology, Cardiovascular Research Institute, School of Medicine, University of California San Francisco, San Francisco, CA (A.Z.M., J.J.M.).

    4 shared publications
  • Bénédicte Lebrun-Vignes

    Sorbonne Université, INSERM CIC-1421, AP-HP, Regional Pharmacovigilance Center, Pitié-Salpêtrière Hospital, UNICO-GRECO.6 Cardio-Oncology Program, Department of Pharmacology, Paris, France

    2 shared publications
  • D.B. Johnson

    Departments of Medicine and Pharmacology, Cardio-oncology program, Vanderbilt University Medical Center, Nashville, USA

    2 shared publications
  • A. Hertig

    Department of Renal Transplantation, Sorbonne University, AP-HP Pitié-Salpêtrière University Hospital, Paris, France

    1 shared publication
  • Aaron W. Aday

    Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    1 shared publication

Latest Publications

  • Solid organ transplant rejection associated with immune-checkpoint inhibitors

    by S. Saberianfar, L.S. Nguyen, A. Manouchehri, B. Lebrun-Vignes, J.J. Moslehi, D.B. Johnson, A. Hertig, J.-E. Salem


    • 26 February 2020
      • Vol. 39  (4) , 344-347

    Evaluation of frequency of autoimmune hepatitis autoantibodies in children with type 1 diabetes.

    by Naser Honar, Zohreh Karamizadeh, Majid-Vares Vazirian, Keramatallah Jahanshahi, Ali Manouchehri, Seyed Mohsen Dehghani, Hazhir Javaherizadeh

    Diabetes mellitus type 1 (T1DM) is one of the childhood diseases with growing prevalence. Various accompanying autoimmune diseases were seen with type 1 diabetes. The most common autoimmune diseases with T1DM are autoimmune thyroiditis and celiac disease. In some reports, autoimmune hepatitis has been reported in association with DM-1. The aim of this study was to evaluate autoimmune hepatitis autoantibodies in children with T1DM. In this crosssectional study, 202 children with T1DM were evaluated (47.5% were males and 52.5% were girls). Liver enzymes, autoimmune hepatitis related autoantibodies such as anti-nuclear antibodies (ANA), anti-smooth muscle (ASMA) and anti liver and kidney microsomal antibodies (LKM-1) were measured. Liver ultrasound was done for participants and biopsy of liver was taken for children with increased echogenicity of the liver, hepatomegaly or elevated liver enzymes. Results analyzed by statistical software spss-16, Descriptive statistics and chi-square test, paired T-TEST. Level of less than 5% was considered statistically significant. In 6 patients ANA and in 4 patients (2%) ASMA was positive,1 patient was ASMA positive but ANA negative. None of the patients were Anti LKM-1 positive. 3 patients had positive ANA and ASMA, and increased liver echogenicity on ultrasound simultaneously. Histological evaluation was showed that 2 patients had findings in favor of autoimmune hepatitis. Auto antibodies were positive in 10 cases. ANA was positive in 6 (2.97%) of all cases. ASMA was positive in 4 (1.98%) cases. Increased echogenicity was found in 3 cases. Histological evaluation showed 2 patients had biopsy confirmed autoimmune hepatitis. AIH-2 was not seen among our cases.


  • Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events

    by Ali Manouchehri, Elishama Kanu, Michael J. Mauro, Aaron W. Aday, Jonathan R. Lindner, Javid Moslehi

    Targeted oncology therapies have revolutionized cancer treatment over the last decade and have resulted in improved prognosis for many patients. This advance has emanated from elucidation of pathways responsible for tumorigenesis followed by targeting of these pathways by specific molecules. Cardiovascular care has become an increasingly critical aspect of patient care in part because patients live longer, but also due to potential associated toxicities from these therapies. Because of the targeted nature of cancer therapies, cardiac and vascular side effects may additionally provide insights into the basic biology of vascular disease. We herein provide the example of tyrosine kinase inhibitors utilized in chronic myelogenous leukemia to illustrate this medical transformation. We describe the vascular considerations for the clinical care of chronic myelogenous leukemia patients as well as the emerging literature on mechanisms of toxicities of the individual tyrosine kinase inhibitors. We additionally postulate that basic insights into toxicities of novel cancer therapies may serve as a new platform for investigation in vascular biology and a new translational research opportunity in vascular medicine.


  • Phénotype et pronostic des atteintes systémiques induites sous inhibiteurs de check-points immunitaires

    by C. Anquetil, J.E. Salem, A. Manouchehri, O. Lambotte, B. Lebrun-Vignes, J.P. Spano, D. Klatzmann, M. Rosenzwajg, B. Fautrel, J. Cadranel, et al.

  • Top Cited Papers

    Cardiovascular Toxicities Associated With Ibrutinib

    by Joe-Elie Salem, Ali Manouchehri, Marie Bretagne, Bénédicte Lebrun-Vignes, John D. Groarke, Douglas B. Johnson, Tao Yang, Nishitha M. Reddy, Christian Funck-Brentano, Jennifer R. Brown, et al.


  • Open Access

    Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition

    by Wendy J. Bottinor, Megan M. Shuey, Ali Manouchehri, Eric H. Farber-Eger, Meng Xu, Devika Nair, Joe-Elie Salem, Thomas J. Wang, Evan L. Brittain


  • Open Access

    Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

    by Douglas B. Johnson, Ali Manouchehri, Alexandra M. Haugh, Henry T. Quach, Justin M. Balko, Benedicte Lebrun-Vignes, Andrew Mammen, Javid J. Moslehi, Joe-Elie Salem

    Background Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including the spectrum, timing, and outcomes, of ICI-induced neurologic toxicities are not well characterized. Methods We performed disproportionality analysis using Vigibase, the World Health Organization pharmacovigilance database, comparing neurologic adverse event (AE) reporting in patients receiving ICIs vs. the full database. Neurologic AEs were classified by group queries using Medical Dictionary for Regulatory Activities, between database inception to September 28, 2018. Associations between ICIs and neurologic AEs were assessed using reporting odds ratios (ROR) and information component (IC). IC compares observed and expected values to find associations between drugs and AEs using disproportionate Bayesian reporting; IC025 (lower end of the IC 95% credibility interval) > 0 is considered statistically significant. Results Among the full database, 18,518,994 AEs were reported, including 48,653 with ICIs. ICIs were associated with higher incidence of myasthenia gravis (0.47% of ICI reports vs. 0.04% of the full database, ROR 16.5 [95% CI 14.5–18.9]; IC025 3.31), encephalitis (0.51% vs. 0.05%, ROR 10.4 [95% CI 9.2–11.8]; IC025 3.15), peripheral neuropathy (1.16% vs. 0.67%, IC025 0.68), and meningitis (0.15% vs. 0.06%, ROR 3.1 [95% CI 2.5–3.9]; IC025 1.01). Myasthenia gravis and encephalitis were associated with anti-PD-1 whereas other neurologic AEs were associated with anti-CTLA-4. Myasthenia gravis was characterized by high fatality rates (~ 20%), early onset (median 29 days), and frequent concurrent myocarditis and myositis; whereas other neurologic AEs had lower fatality rates (6–12%), later onset (median 61–80 days), and were non-overlapping. Conclusions ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations.


  • Top Cited Papers

    Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

    by Joe-Elie Salem, Ali Manouchehri, Melissa Moey, Bénédicte Lebrun-Vignes, Lisa Bastarache, Antoine Pariente, Aurélien Gobert, Jean-Philippe Spano, Justin M Balko, Marc P Bonaca, et al.